Janux Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
JANX$12.04-5.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
(in thousands)
| Year EndedDecember 31, | |||
|---|---|---|---|
| 2024 | 2023 | 2022 | |
| Cash flows from operating activities | |||
| Net loss | $(68,994) | $(58,293) | $(63,059) |
| Adjustments to reconcile net loss to net cash used in operating activities: | |||
| Depreciation | 2,060 | 1,955 | 841 |
| Stock-based compensation | 33,020 | 20,005 | 17,203 |
| Accretion of discounts on investments, net | (10,585) | (7,688) | (2,183) |
| Changes in operating assets and liabilities: | |||
| Prepaid expenses and other current assets | (3,280) | 210 | (3,369) |
| Other long-term assets | (375) | (1,119) | (1,270) |
| Accounts payable | 1,584 | 277 | (294) |
| Accrued expenses | 4,426 | (678) | 4,156 |
| Deferred revenue | (1,705) | (5,922) | 1,764 |
| Operating lease right-of-use assets and liabilities, net | 35 | 678 | 3,289 |
| Net cash used in operating activities | (43,814) | (50,575) | (42,922) |
| Cash flows from investing activities | |||
| Purchases of property and equipment | (359) | (1,850) | (6,445) |
| Purchases of short-term investments | (470,577) | (317,344) | (294,389) |
| Maturities of short-term investments | 212,915 | 278,000 | 359,100 |
| Net cash provided by (used in) investing activities | (258,021) | (41,194) | 58,266 |
| Cash flows from financing activities | |||
| Proceeds from exercise of common stock options and employee stock purchase plan | 14,968 | 3,018 | 500 |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | 698,267 | 56,530 | — |
| Net cash provided by financing activities | 713,235 | 59,548 | 500 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 411,400 | (32,221) | 15,844 |
| Cash, cash equivalents and restricted cash – beginning of year | 20,021 | 52,242 | 36,398 |
| Cash, cash equivalents and restricted cash – end of period | $431,421 | $20,021 | $52,242 |
| Supplemental disclosure of noncash investing and financing activities | |||
| Unpaid property and equipment | $6 | $132 | $109 |
| Unpaid issuance costs | $347 | $— | $— |
| Vesting of restricted common stock | $20 | $149 | $1,034 |
| Unrealized gain (loss) on available-for-sale securities, net | $1,498 | $2,200 | $(1,265) |
| Operating lease liabilities arising from right-of-use assets | $— | $— | $23,422 |
Notes to Financial Statements
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.